Table 5 Factors influencing MSI testing in all CRC patients
From: Analysis of factors influencing molecular testing at diagnostic of colorectal cancer
MSI testing N = 138/1269 (10.9%) | Univariate analysis P-Value | Multivariate analysis | |||
|---|---|---|---|---|---|
Odds ratio | IC 95% | P-Value | |||
Age (years) | < 0.0001 | < 0.0001 | |||
> 75 | 10 / 553 (1.8%) | 1 | Ref | ||
60–75 | 46 / 508 (9.1%) | 5.77 | 2.80–11.89 | ||
< 60 | 82 / 208 (39.4%) | 59.6 | 27.82–127.85 | ||
Sex | 0.88 | 0.21 | |||
Women | 62 / 578 (10.7%) | 1 | Ref | ||
Men | 76 / 691 (11.0%) | 0.75 | 0.47–1.18 | ||
Site of the primary tumour | 0.53 | ||||
Rectum | 31 / 309 (10.0%) | ||||
Right colon | 44 / 437 (10.1%) | ||||
Left colon | 63 / 523 (12.1%) | ||||
TNM stage | < 0.001 | 0.0001 | |||
I | 6 / 219 (2.7%) | 1 | Ref | ||
II | 37 / 380 (9.7%) | 8.62 | 3.17–23.41 | ||
III | 49 / 380 (12.9%) | 7.96 | 3.00–21.12 | ||
IV | 46 / 290 (15.9%) | 8.79 | 3.29–23.48 | ||
Tumour grade (MD = 173) | 0.34 | ||||
Well | 55 / 436 (12.6%) | ||||
Moderate | 56 / 576 (9.7%) | ||||
Poor | 9 / 84 (10.7%) | ||||
Geographical area of primary treatment (MD = 4) | < 0.0001 | < 0.0001 | |||
Charente-Maritime | 3 / 392 (0.8%) | 1 | Ref | ||
Charente | 21 / 226 (9.3%) | 17.08 | 4.78–61.00 | ||
Deux-Sèvres | 19 / 227 (8.4%) | 13.98 | 3.89–50.24 | ||
Vienne | 80 / 301 (26.6%) | 69.59 | 20.51–236.01 | ||
Outside the region | 15 / 119 (12.6%) | 13.53 | 3.64–50.29 | ||
Status of the center (MD = 4) | < 0.0001a | ||||
Public Hospital | 36 / 551 (6.5%) | – | – | – | |
Private hospital | 47 / 512 (9.2%) | ||||
University hospital | 55 / 202 (27.2%) | ||||